Background: We hypothesized that anemia could represent one of the major factors influencing the outcome of patients undergoing neo-adjuvant treatment of rectal cancer.
background Anemia is common in cancer patients, especially among those receiving myelosuppressive chemotherapy and radiotherapy. The relationship between hemoglobin (Hb) levels and healthrelated quality of life is well known and justifies the correction of anemia in clinical practice.
On the other hand, correction of anemia by blood transfusions may be dangerous, not only by increasing the risk of infections and hemolytic reactions but also because they seem to cause an immunodepression determined by linfocytes interfering with the outcome of cancer treatments [1] .
In fact, anemia is a proved predictive factor for radiosensitivity. Schwartz [2] showed that hypoxia reduces the radiosensitivity of cells and Hollaendre et al. [3] defined the necessity to increase dose radiation in hypoxygenated tissues. The outcomes following curative-intent radiation therapy are adversely influenced by poor i.t. oxygenation and the presence of anemia [4] [5] [6] . Recently, Harrison et al. [7] showed that i.t. hypoxia may directly contribute to genomic instability and mutagenesis.
Since most cancers may benefit from a combination of chemotherapy and radiotherapy, anemia may represent a crucial factor in order to obtain favorable clinical results in these patients. The analysis of the relationship between anemia and outcome in several tumors seems to support this hypothesis.
A Canadian retrospective experience noticed that a higher average weekly nadir Hb correlated with a better overall survival (OS) rate in patients affected by cervical cancer undergoing radiation treatment [8] . Obermeier et al. [9] confirmed that the nadir Hb level is a prognostic relevant factor predicting the clinical response to chemoradiation in cervical cancer patients receiving chemoradiation.
Similar results were found in head and neck cancer patients. Different studies conducted in patients with these tumors have revealed Hb level as a powerful prognostic factor for locoregional tumor control [10] [11] [12] [13] [14] [15] , disease-free survival (DFS) [16] and OS [10, 12, 13, 15] . Recently, anemia has been introduced as a factor of a prognostic index score in metastatic nasopharyngeal carcinoma [17] . Furthermore, Wagner et al.
original article [18] showed that Hb levels at the end of radiochemotherapy strongly correlate to the pathohistologic response in the surgical specimen.
The prognostic role of anemia has also been investigated in lung cancer patients. In an analysis of nine trials carried out by the Radiation Oncology Therapy Group, an univariate analysis revealed that Hb <12 mg/dl was predictive of outcome with a difference of 2 months in median OS [19] . MacRae et al. [20] evaluated 104 patients with stage III non-small-cell lung cancer (NSCLC) undergoing chemoradiotherapy and showed that declining Hb during treatment had a statistically significant impact on survival. More recently, Pradier et al. [21] showed that the Hb levels before radiochemotherapy have an influence on prognosis of NSCLC, where lower levels were associated with worse outcome. Furthermore, some data support the hypothesis that pathologic responses to preoperative chemoradiation of NSCLC improve with increasing Hb levels [22] .
Another tumor that in last years obtained a benefit from the combined treatment of chemotherapy and radiotherapy is locally advanced rectal cancer. A preoperative chemoradiotherapy has been recognized as a standard approach in the management of these patients. Since most of rectal cancer patients, because of bleeding or other clinical conditions, may be anemic, we assessed the correlation of preoperative anemia and outcome in patients with locally advanced rectal cancer undergoing neo-adjuvant treatment.
patients and methods

patients selection
The study included patients with histological proven rectal adenocarcinoma who underwent preoperative concomitant chemoradiotherapy in three Medical Oncology Italian Centers from June 1996 to December 2003.
Patients were requested to be older than 18 years and with a good performance status (Karnofsky Score ‡70). Written informed consent was obtained. Patients with other malignancies, bowel chronic inflammatory disease, contraindication to chemotherapy or life expectancy <1 year were excluded.
Data for patients entered on to the analysis included age, sex, type of surgery, histological type, clinical pretreatment stage and post-treatment pathological stage of disease, preoperative and postoperative Hb levels.
Preoperative Hb level was defined as the level of Hb at the beginning of treatment; while post-treatment Hb level was considered the value recorded before surgery.
Pretreatment tumor and nodal stage were assessed by abdomen-pelvischest computed tomography scan and magnetic resonance imaging; an intra-rectum ultrasound was also carried out. Before starting therapy, complete blood count, renal function and liver function were recorded. Neo-adjuvant treatment was decided according to the policy of the center and consisted of radiotherapy alone or concomitant radiochemotherapy. Chemotherapy was fluorouracil-based regimens. Surgery was planned 4-6 weeks after the completion of chemoradiotherapy. Resected samples were analyzed histologically in order to define the pathological tumor and nodal stage.
data management and statistical analysis
Primary end point of this study was to evaluate the prognostic role of anemia. OS was defined as the interval between the start of the treatment to death or last follow-up visit. DFS was defined as the interval between surgery and date of progression or death or last follow-up visit. We compared OS and DFS among subgroups of patients according to the Hb level.
The association between categorical variables was estimated by chi-square test.
Cox multiple regression analysis was used to assess the role of those variables resulted significant at univariate analysis [23] .
Survival distribution was estimated by the Kaplan-Meier method. Significant differences in probability of surviving between the strata were evaluated by log-rank test.
A significant level of 0.05 was chosen to assess the statistical significance. Statistical analyses were carried out using the SAS software version 8.2 for Windows (SAS Institute Inc., Cary, NC, USA).
results
Three hundred and seventeen patients with rectal cancer received neo-adjuvant concomitant chemoradiotherapy. Table 1 summarizes the patients' characteristics. Seventy-five (23.7%) patients received radiotherapy alone and 242 (76.3%) patients received concomitant chemoradiotherapy. Chemotherapy consisted of fluoropyrimidines alone in 149 patients (47%) and fluoropyrimidines in combination with other agents (cisplatin, oxaliplatin or mitomycin C) in 93 (29.3%) patients. The majority of patients (60.3%) underwent anterior resection of rectum. Miles was necessary in 81 patients (25.5%) and proctocolectomy in 22 patients (7%). All the patients underwent radical resection with surgical margins >1 cm. Local recurrences were observed in 53 patients (16.7%) while distant metastasis appeared in 25 out of the above-mentioned 53 cases.
Pretreatment Hb level ranged from 7.9 to 17.9 g/dl (median 14.05 g/dl). Only one patient had Hb <8 g/dl during the treatment and he was given a blood transfusion. Erythropoietic growth factors were used in only one patient. We recorded a decrease of the Hb level after treatment completion in 179 patients.
When considering DFS, there was a significant difference in subgroups of patients with lower levels of Hb. In particular, DFS was worse in patients with Hb £12 g/dl (group 1) versus Hb >12 g/dl (group 2, P = 0.0183) (Figure 1) . The role of the Hb level seemed to be confirmed further by the clinical downstaging obtained in 55% of patients in group 2, in comparison with 35% of the patients achieving a significant downstaging in group 1 (P = 0.05).
At univariate and multivariate analysis, including the following characteristics: age, sex, histology, type of surgery, neo-adjuvant treatment and Hb level, only the Hb level (group 1: £12 g/dl versus group 2: >12 g/dl) resulted in a significant factor for DFS (Table 2) . No significant differences in the overall patient survival were observed on the basis of the Hb level, even if a trend of survival benefit was present in the group of patients with a better Hb level (P = 0.097). The relatively short follow-up could justify the absence of a significant difference. Our results seem to show that, even in rectal cancer patients receiving neo-adjuvant chemoradiotherapy, anemia is able to predict clinical response to treatment.
According with our findings, several studies indicated a defined role of pretreatment Hb value. However, most of these data come from retrospective analyses and other trials did not confirm these results. MacRae et al. [20] demonstrated that presenting Hb, average Hb and minimum Hb level during therapy were not statistically significant predictive of survival in NSCLC patients, while declining Hb during chemoradiotherapy had a significant improvement on OS. A decrease of Hb level from 13.8 to 12.8 g/dl resulted in a 6% decrease in locoregional tumor control (P = 0.006) in early larynx cancer patients. In other groups of head and neck cancer patients, the posttreatment Hb value correlated with DFS [14] .
In fact, by dividing our patients in two groups according to patients' Hb level (group 1: £12 g/dl; group 2: >12 g/dl), we found that the tumor clinical downstaging was better in group 2, emphasizing the already known role of anemia as predictive factor for radiosensitivity. Furthermore, we observed a better DFS in non-anemic patients, indicating that anemia can be considered a prognostic factor in patients undergoing neoadjuvant treatment with curative intent for rectal cancer. Box et al. [24] has recently analyzed a series of 100 patients with rectal cancer and found similar results: non-anemic patients achieved better tumor response and experienced less local recurrence (7% versus 38% P = 0.003) than anemic patients. Also the 2-year survival rate was improved in non-anemic patients (91% versus 64%, P = 0.021). Although we found a significant difference in DFS between patients who presented anemic or did not, the difference we observed in OS did not Annals of Oncology original article reach the statistical significance. This did not surprise us, since median follow-up of our sample is too short to show significant difference. In fact, given that most rectal cancers relapse within 1 year, the number of events was sufficient to detect a difference in DFS, while we probably need a longer follow-up to reveal an improvement in OS especially in non-anemic patients. Despite the association between anemia and poor prognosis in patients who are treated with chemoradiotherapy for solid tumors, there is no clear evidence whether anemia exerts an independent prognostic impact or whether anemia represents only an epiphenomenon indicating that anemia is linked to adverse prognostic factors such as large volume tumors. However, in a recent study, where the relationship between pretreatment anemia and survival was investigated in surgically treated patients with gastric cancer, the 10-year survival rate was better in non-anemic patients, but this difference was statistically significant only for tumors at I and II stages, where other likely prognostic factors were less influential on the outcome [25] .
Moreover, it is unclear how far the correction of the anemia might have impact on prognosis. Since the use of erythropoietic agents has shown to improve survival in cancer patients, the correction of anemia should be considered for patients presenting with low Hb levels. This is supported by a retrospective study which looked at the comparison among patients with Hb >14.5g/dl, patients with Hb <14.5 g/dl and patients with Hb <14.5 g/dl who were given erythropoietin alpha. Anemic patients had the worst outcome, but there was no difference between patients who started with a normal Hb value and those who were initially anemic but received erythropoietic growth factors [26] .
In conclusion, although further investigations are needed, pretreatment anemia seems to be a prognostic factor for rectal cancer patients undergoing neo-adjuvant chemoradiotherapy and, since this is a modifiable factor, the correction of anemia could be advisable.
These results prompted us to investigate two different approaches. The first one is to correct anemia earlier by the use of epoetin. Alternatively, we are assessing the effect of anemia on tumor hypoxia and on the alterations of genes involved in the hypoxia (HIF, CRC-1, VEGF) that may be responsible for a more aggressive behavior of tumors, in order to develop more effective adjuvant therapies by using novel agents able to inhibit the expression of the genes (VEGF; COX2; HIF inhibitors).
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